[Induction by local injections of IL-2 of antitumor effector cells and secondary production of cytokines in malignant pleural effusion].
The present study was undertaken to examine the effects of intrapleural administration of IL-2 on induction of cytotoxic killer cells and on secondary production of cytokines in malignant pleural effusions. During daily local administration of IL-2, significant in vivo induction of cytotoxic activity was observed after 3-7 days, followed by a decrease in this activity in pleural mononuclear cells (MNC) to almost zero by day 15. IL-4 suppressed induction of IL-2-inducible killer cells from MNC in blood and pleural effusion, but significantly augmented the killer induction from pleural effusion MNC obtained after local 7-day administration of IL-2. Before therapy, malignant pleural effusions contained various levels of IL-6 and M-CSF, but no IL-4 or IFN-gamma. Daily intrapleural instillation of IL-2 resulted in significant augmentation of the levels of IL-4, IL-6, IFN-gamma and M-CSF. Chromatographical fractionation of the pleural effusion showed only one major peak with a MW of 24 kD, which had IL-6 activity. The level of the latent form of TGF-beta also increased during local IL-2 therapy. In contrast, significant levels of TNF (alpha, beta), IL-1 beta or IFN-alpha were not detectable in pleural effusions before or during therapy. These data suggest that IL-2 is an important inducer of secondary production of various cytokines in vivo, responsible for up- or down-regulation of induction of IL-2-inducible killer activity.
Sone
S
S
Third Department of Internal Medicine, University of Tokushima School of Medicine, Japan.
Yanagawa
H
H
Nii
A
A
Ozaki
T
T
Ogura
T
T
D016207:Cytokines / Q000096:biosynthesis*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D015552:Injections, Intralesional; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D008175:Lung Neoplasms / Q000150:complications*; D008213:Lymphocyte Activation; D016066:Pleural Effusion, Malignant / Q000209:etiology / Q000378:metabolism / Q000628:therapy*
D016207:Cytokines; D007376:Interleukin-2